DENVER, Sept. 13,
2022 /PRNewswire/ -- DaVita Inc. announced
today that its Board of Directors appointed a new independent
director, Adam H. Schechter, to join
the Board, effective September 20,
2022.
Mr. Schechter is the President, Chief Executive Officer and
Chair of the Board of Directors of Laboratory Corporation of
America Holdings ("Labcorp"), a leading global life sciences
company with $16.1 billion in
reported revenues in 2021. Mr. Schechter has served as
President and CEO of LabCorp since November
2019, as a director since April
2013 and as Chair of the Board since May 2020.
"Adam's broad purview of the health care ecosystem, values-based
approach and experience with scaled, decentralized operations will
be a great addition to our Board," said Javier Rodriguez, CEO
of DaVita Inc.
Mr. Schechter brings to the Board decades of leadership and
experience in the public company and health care sectors, having
served as an independent director of LabCorp since 2013 prior to
taking the position as chief executive, and having worked for more
than 30 years at Merck & Co., Inc., a multinational
pharmaceutical company. During his time at Merck, Mr. Schechter
served as Executive Vice President from 2010 to 2018, where he was
a member of Merck's executive committee and pharmaceutical and
vaccines operating committee, and President of Merck's Global Human
Health Division, which includes the company's worldwide
pharmaceutical and vaccine businesses. Prior to becoming President,
Global Human Health, Mr. Schechter served as President, Global
Pharmaceutical Business of Merck from 2007 to 2010. Mr. Schechter's
extensive experience at Merck included global and U.S.-focused
leadership roles spanning sales, marketing, and managed markets, as
well as business and product development. He is a Board Member for
Water.org, a global nonprofit organization working to bring water
and sanitation to the world, and an executive board member for the
National Alliance for Hispanic Health. In 2022, Mr. Schechter
earned the CERT Certificate in Cybersecurity Oversight.
"I was drawn to DaVita's unwavering commitment to the patient
experience and delivering better health outcomes," said Mr.
Schechter. "Joining the Board creates an exciting opportunity to
share my perspective and support its mission of being the provider,
partner and an employer of choice."
Mr. Schechter will serve on the Audit Committee and Compliance
& Quality Committee of DaVita's Board, each effective
September 20, 2022.
"Adam's proven track record of corporate leadership, passion and
innovation make him a great addition to the team," said
Pam Arway, independent chair of the
DaVita Inc. Board of Directors.
With the addition of Mr. Schechter, the DaVita Board is
comprised of ten highly qualified directors, with 20% racial/ethnic
and 30% gender diversity.
To learn more about DaVita and its Board of Directors, visit
DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on
transforming care delivery to improve quality of life for patients
around the globe. The company is one of the largest providers of
kidney care services in the U.S. and has been a leader in clinical
quality and innovation for more than 20 years. As of June 30, 2022 DaVita served 198,000 patients at
2,810 outpatient dialysis centers, at home, and in the hospital in
the United States. The company
also operated 349 outpatient dialysis centers in eleven countries
worldwide.
Media Contact:
Investor Relations
IR@davita.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/davita-announces-adam-h-schechter-to-join-its-board-of-directors-301623667.html
SOURCE DaVita Inc.